Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award

Posted on by ScienceFather

Assoc. Prof. Dr. Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award

Associate Professor from Department of Physiology, China Medical University, Taiwan

Yi-Ping Huang is an accomplished Associate Professor in the Department of Physiology at China Medical University, with over 32 years of experience in both teaching and research. His primary focus is on cancer treatment, specifically investigating the therapeutic effects of natural and synthetic compounds on cancer cells. Over the years, Huang has significantly contributed to the field, publishing numerous peer-reviewed articles and advancing the understanding of cancer treatment mechanisms, particularly apoptosis, DNA damage, and anti-metastasis pathways. His expertise extends to drug synergy, especially in combination with chemotherapy. He has also been involved in teaching innovations in physiology, emphasizing student engagement and educational research. Huang’s extensive research output and leadership in the field have made him a well-respected figure in the scientific community, as reflected in his numerous research projects and academic publications.

Professional Profile

Education

Yi-Ping Huang completed his undergraduate studies in Physiology at Yang-Ming University, laying the foundation for his extensive career in research and academia. His academic journey provided a strong base for his research into cancer treatment and physiological mechanisms. This solid educational background enabled Huang to develop expertise in a range of specialized topics, particularly in the therapeutic effects of natural compounds. Over the years, his continuous learning and commitment to his field have propelled his success, making him an established academic in the study of cancer therapy and physiology.

Professional Experience

Yi-Ping Huang has a long and distinguished career in both academia and research. As an Associate Professor at China Medical University, he has been instrumental in educating students and conducting cutting-edge research on cancer therapy. With over three decades of experience, Huang has led numerous research projects focusing on natural and synthetic compounds in cancer treatment. His role also includes teaching and mentoring students, guiding them in the latest scientific advancements. Huang’s professional experience is marked by extensive publications in high-impact journals, further showcasing his contributions to the scientific community and his leadership in advancing cancer research.

Research Interests

Yi-Ping Huang’s primary research interests revolve around the use of natural and synthetic compounds in cancer therapy. His work explores the mechanisms through which these compounds induce apoptosis, DNA damage, and inhibit metastasis in cancer cells. Huang is particularly focused on understanding how these compounds can synergize with chemotherapy drugs to overcome resistance and improve treatment outcomes. His ongoing research also investigates the therapeutic effects of compounds such as Demethoxycurcumin (DMC), Phenethyl Isothiocyanate (PEITC), and PW06 in various cancer types, including glioblastoma and colon cancer. These areas of interest align with his goal of advancing cancer therapy through the identification and development of novel therapeutic agents.

Research Skills

Yi-Ping Huang’s research skills are extensive and diverse, ranging from molecular biology techniques to cancer therapy research. He possesses a deep understanding of cancer cell biology, particularly in apoptosis, DNA repair, and metastasis inhibition. Huang has demonstrated proficiency in the use of various experimental models to study the effects of natural and synthetic compounds on cancer cells, including in vitro and in vivo models. His expertise extends to studying drug interactions and mechanisms of drug resistance, especially in relation to chemotherapy. Huang’s interdisciplinary approach to research, combining pharmacology, molecular biology, and cancer therapy, has led to groundbreaking studies that have contributed significantly to the field.

Awards and Honors

Throughout his illustrious career, Yi-Ping Huang has received numerous awards and honors that recognize his contributions to the scientific community. His groundbreaking research in cancer therapy, particularly in the use of natural and synthetic compounds, has earned him accolades from academic institutions and scientific organizations. Huang’s work on compounds such as Demethoxycurcumin and Phenethyl Isothiocyanate has been widely recognized in the field of oncology research. His consistent contributions to cancer treatment research and his leadership in academia have earned him recognition as a leading expert in his field, enhancing his reputation as an influential figure in cancer research.

Conclusion

Yi-Ping Huang’s career has been defined by significant contributions to cancer research, particularly in the development and understanding of natural and synthetic compounds as therapeutic agents. His research focuses on the molecular mechanisms of apoptosis, DNA damage, and anti-metastasis, offering potential for groundbreaking advancements in cancer treatment. With over three decades of experience, Huang’s work continues to influence both basic and clinical cancer research. His leadership in academia, coupled with his innovative research, positions him as a respected figure in the scientific community. As he continues to push the boundaries of cancer therapy, his contributions are likely to have a lasting impact on the field.

Publication Top Notes

M084 causes cell cycle arrest and inhibits voltage-gated Na⁺ and K⁺ channels in neuronal N2A cells
Authors: Iat Lon Leong, Chinmin Chuang, Chenghsun Wu, Yukman Leung, Yiping Huang
Year: 2025

2. MCU-i4, a mitochondrial Ca²⁺ uniporter modulator, induces breast cancer BT474 cell death by enhancing glycolysis, ATP production and reactive oxygen species (ROS) burst
Authors: Edmund Cheung So, Louis Wing Cheong Chow, Chinmin Chuang, Yukman Leung, Yiping Huang
Year: 2025

3. Physalin A induces apoptosis through conjugating with Fas-FADD cell death receptor in human oral squamous carcinoma cells and suppresses HSC-3 cell xenograft tumors in NOD/SCID mice
Authors: Fu Shin Chueh, Shengyao Hsu, Kuangchi Lai, Yiping Huang, Wen Tsong Hsieh
Year: 2025

4. PEITC Induces DNA Damage and Inhibits DNA Repair-Associated Proteins in Human Retinoblastoma Cells In Vitro
Authors: Shengyao Hsu, Yiping Huang, Techun Hsia, Fu Shin Chueh, Chaolin Kuo
Year: 2024

5. Armillaria mellea Mycelia Alleviate PM2.5-Induced Pulmonary Inflammation in Murine Models
Authors: Yiping Huang, Yutsen Huang, Huiyu Wu, Chinchu Chen, Chih Ho Lai
Year: 2024

6. RAGE participates in the intracellular transport of Campylobacter jejuni cytolethal distending toxin
Authors: Yufang Chang, Yiping Huang, Chiahuei Chou, Chenghsun Chiu, Chih Ho Lai
Year: 2024
Citations: 2

7. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mTOR/NF-κB and MMP2/MMP9 signaling pathways in vitro
Authors: Yiping Huang, Chunan Yeh, Yishih Ma, Jin Cherng Lien, Wen Tsong Hsieh
Year: 2024
Citations: 2

Sutha Devaraj | Pharmaceutical Science | Best Academic Researcher Award

Posted on by ScienceFather

Dr. Sutha Devaraj | Pharmaceutical Science | Best Academic Researcher Award

Deputy Dean from Perdana University, Malaysia 

Sutha Devaraj is a dedicated researcher and academician with expertise in pharmaceutical sciences, specializing in drug discovery and pharmacology. She earned her Ph.D. in Pharmaceutical Sciences from Universiti Sains Malaysia (USM) in 2018, where her research focused on the development of optimized methods for preparing bioactive fractions of Strobilanthes crispus (L.) Bremek. Her work involved the quantification of the plant’s marker compound, contributing to advancements in natural product-based drug discovery. Before completing her Ph.D., Sutha obtained a Master’s in Pharmacology from USM in 2012. Her master’s thesis focused on the hepatoprotective properties of Curcuma xanthorrhiza Rox, exploring its potential for liver protection through its bioactive compounds. She also holds a B.Sc. (Hons) in Biotechnology from AIMST University, Malaysia, where she graduated with a CGPA of 3.41. This academic foundation in biotechnology provided her with a strong understanding of molecular biology and biochemistry, essential for her later research in pharmacology and drug development. Throughout her career, Sutha has contributed significantly to the study of plant-based compounds with medicinal properties, and her work has enhanced the understanding of their therapeutic potential. Her academic journey has been marked by a consistent focus on integrating practical research with innovative approaches in pharmaceutical sciences.

Professional Profile

Education

Sutha Devaraj’s educational background is distinguished by her specialized studies in pharmaceutical sciences and pharmacology. She earned her Ph.D. in Pharmaceutical Sciences with a focus on Drug Discovery from Universiti Sains Malaysia (USM) in 2018. Her doctoral thesis, titled Development of an Optimized Method for the Preparation of Bioactive Fraction of Strobilanthes crispus (L.) Bremek and the Quantification of its Marker Compound, was instrumental in advancing research on bioactive compounds derived from natural sources. This work enhanced the understanding of the therapeutic potentials of Strobilanthes crispus, contributing to both pharmaceutical science and ethnomedicine. Before completing her Ph.D., Sutha obtained her Master of Science (M.Sc.) in Pharmacology from USM in 2012. Her research focused on the hepatoprotective and pharmacological properties of Curcuma xanthorrhiza Rox, and she published findings related to the effectiveness of its standardized ethanolic extract in protecting the liver, demonstrating her expertise in pharmacological testing and drug development. Sutha’s academic journey began with a Bachelor of Science (B.Sc.) in Biotechnology (Hons) from AIMST University in 2008, where she graduated with a CGPA of 3.41. This early foundation in biotechnology paved the way for her subsequent advanced studies in pharmacology and pharmaceutical sciences.

Professional Experience

Sutha Devaraj has accumulated significant experience in the field of pharmaceutical sciences and pharmacology. Throughout her career, she has worked with various academic and research institutions, where she has contributed to advancing the understanding of pharmacological mechanisms and drug discovery. As a researcher at Universiti Sains Malaysia (USM), Sutha has actively participated in projects focusing on the isolation and quantification of bioactive compounds from plants, which has led to important findings on their therapeutic potentials. She has collaborated with both local and international researchers to examine the pharmacological properties of natural products, a focus that has shaped her work in drug discovery. In addition to her research roles, Sutha has also contributed to teaching and mentoring undergraduate and postgraduate students. She has shared her expertise in pharmacology and biotechnology, helping shape the next generation of scientists. Through her work, Sutha has built a strong professional reputation, earning recognition for her in-depth understanding of drug development processes and her ability to implement novel methodologies in her research.

Research Skills

Sutha Devaraj possesses a wide array of research skills essential to her work in pharmaceutical sciences and pharmacology. Her proficiency in bioactive compound isolation and quantification has been demonstrated through her research on Strobilanthes crispus and Curcuma xanthorrhiza, both of which are significant to natural drug discovery. She is highly skilled in pharmacological testing, utilizing a range of in-vitro and in-vivo models to assess the therapeutic efficacy of plant-based extracts. In addition to her experimental capabilities, Sutha has expertise in analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry, which she has used to identify and quantify bioactive compounds in complex matrices. Her background in biotechnology provides her with a solid understanding of biochemical assays, including enzyme inhibition and receptor binding assays. Furthermore, Sutha has honed her skills in data analysis and interpretation, often using sophisticated statistical tools to evaluate research results. Her ability to combine these skills allows her to contribute to cutting-edge research in drug discovery, particularly in exploring new therapeutic agents derived from natural sources.

Research Interests

Sutha Devaraj’s research interests lie at the intersection of pharmacology, drug discovery, and natural products. She is particularly focused on the exploration of plant-based bioactive compounds and their potential applications in pharmaceutical development. Her Ph.D. research on Strobilanthes crispus exemplifies her dedication to the discovery of new therapeutic agents from natural resources. Sutha is passionate about investigating the hepatoprotective and anticancer properties of various plant species, particularly those indigenous to Southeast Asia. She is also interested in the mechanisms of action of these compounds, aiming to elucidate how they interact with biological systems to exert therapeutic effects. In addition to pharmacological studies, Sutha is keen on formulation development, specifically in optimizing methods for the preparation and stabilization of bioactive extracts. Her future research endeavors include furthering the development of natural-based drugs with fewer side effects compared to conventional synthetic drugs, contributing to a more sustainable and effective approach in pharmaceutical therapy.

Awards and Honors

Sutha Devaraj’s career has been marked by notable recognition for her academic and research contributions. She was awarded a PhD Fellowship by Universiti Sains Malaysia (USM), providing her with the opportunity to carry out high-impact research in the field of pharmaceutical sciences. Additionally, her M.Sc. research on Curcuma xanthorrhiza earned her accolades for its significance in hepatoprotective studies. Sutha’s ability to combine scientific rigor with practical applications has led to her work being published in well-respected, peer-reviewed journals. Her academic excellence and contributions to the field have earned her membership in several prestigious academic organizations and editorial positions in prominent journals related to pharmacology and drug development. Her work continues to be recognized by the academic community, highlighting her as an emerging leader in her field of expertise.

Conclusion

In conclusion, Sutha Devaraj is an accomplished researcher with a strong academic background and expertise in pharmacology and drug discovery. Her dedication to advancing natural product research has led to valuable contributions in the areas of bioactive compound isolation and pharmacological evaluation. Sutha’s research skills, which include advanced analytical techniques and experimental methodologies, equip her to make meaningful advances in the development of therapeutic agents. Her research interests reflect a deep commitment to exploring sustainable and effective natural-based drugs, particularly those with hepatoprotective and anticancer properties. With a growing reputation in the field, Sutha’s work continues to inspire innovation in the pharmaceutical sciences, and her achievements and contributions make her a prominent figure in the ongoing search for new, safer therapeutic options.

Publications Top Notes

1. Evaluation of the Antinociceptive Activity and Acute Oral Toxicity of Standardized Ethanolic Extract of the Rhizome of Curcuma xanthorrhiza Roxb

  • Authors: S. Devaraj, A.S. Esfahani, S. Ismail, S. Ramanathan, M.F. Yam

  • Journal: Molecules, 15(4), 2925–2934

  • Year: 2010

  • Citations: 97

2. Investigation of Antioxidant and Hepatoprotective Activity of Standardized Curcuma xanthorrhiza Rhizome in Carbon Tetrachloride‐Induced Hepatic Damaged Rats

  • Authors: S. Devaraj, S. Ismail, S. Ramanathan, M.F. Yam

  • Journal: The Scientific World Journal, 2014(1), 353128

  • Year: 2014

  • Citations: 75

3. Evaluation of the Hepatoprotective Activity of Standardized Ethanolic Extract of Curcuma xanthorrhiza Roxb

  • Authors: S. Devaraj, S. Ismail, S. Ramanathan, S. Marimuthu, Y.M. Fei

  • Journal: Journal of Medicinal Plants Research, 4(23), 2512–2517

  • Year: 2010

  • Citations: 53

4. Anti-Tumor Action, Clinical Biochemistry Profile and Phytochemical Constituents of a Pharmacologically Active Fraction of S. crispus in NMU-Induced Rat Model

  • Authors: N.S. Yaacob, H.M. Yankuzo, S. Devaraj, J.K.M. Wong, C.S. Lai

  • Journal: PLoS One, 10(5), e0126426

  • Year: 2015

  • Citations: 41

5. A Study on the Hepatoprotective Effect of Andrographis paniculata (Burm. F) Nees on Mice

  • Author: D. Sutha

  • Journal: Journal of Phytology, 2(11)

  • Year: 2010

  • Citations: 35

6. In Vivo Toxicological Investigations of Standardized Ethanolic Extract of Curcuma xanthorrhiza Roxb. Rhizome

  • Authors: S. Devaraj, S. Ismail, S. Ramanathan, M. FeiYam

  • Journal: Journal of Natural Products and Plant Resources, 3(1), 67–73

  • Year: 2013

  • Citations: 28

7. Explorations of CRISPR/Cas9 for Improving the Long-Term Efficacy of Universal CAR-T Cells in Tumor Immunotherapy

  • Authors: M. Naeem, A. Hazafa, N. Bano, R. Ali, M. Farooq, S.I. Abd Razak, T.Y. Lee, et al.

  • Journal: Life Sciences, 316, 121409

  • Year: 2023

  • Citations: 23

8. Phytochemical, Antioxidant, Antipyretic and Anti-inflammatory Activities of Aqueous-Methanolic Leaf Extract of Mangifera indica

  • Authors: Q.U. Ain, M.O. Iqbal, I.A. Khan, N. Bano, M. Naeem, M.I. Jamaludin, S. Devaraj

  • Journal: American Journal of Translational Research, 15(7), 4533

  • Year: 2023

  • Citations: 15

9. Pathogenetic Mechanisms of Liver-Associated Injuries, Management, and Current Challenges in COVID-19 Patients

  • Authors: M. Naeem, N. Bano, S. Manzoor, A. Ahmad, N. Munawar, S.I.A. Razak, T.Y. Lee, et al.

  • Journal: Biomolecules, 13(1), 99

  • Year: 2023

  • Citations: 10

10. Innovative Aspects and Applications of Single Cell Technology for Different Diseases

  • Authors: A. Ali, S. Manzoor, T. Ali, M. Asim, G. Muhammad, A. Ahmad, M.I. Jamaludin, et al.

  • Journal: American Journal of Cancer Research, 14(8), 4028

  • Year: 2024

  • Citations: 1

11. Understanding the Role of Pharmacology and Toxicology in the Research, Development, and Innovation Process by Analyzing the Drug Development Process

  • Authors: L. Waheed, I. Ur Rehman, S. Devaraj, F.H.G.Q. Al-Amier, P. Jativa, G. Naz, et al.

  • Journal: Journal of Pharmaceutical Negative Results, Vol. 14

  • Year: 2023

  • Citations: 1

Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Professor at Tianjin University of Traditional Chinese Medicine, China

Professor Haiyang Yu is an accomplished researcher and academic in the field of pharmacology and traditional Chinese medicine. With a focus on the anti-tumor molecular mechanisms of natural products, he has significantly contributed to cancer research. His work delves into understanding how small molecules in traditional Chinese medicine and other natural sources can target cancerous cells. Throughout his career, Professor Yu has gained recognition for his work, publishing over 40 peer-reviewed articles, including in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology. He has also led six national research projects. His lab at Tianjin University of Traditional Chinese Medicine explores the pharmacological potential of these compounds, using network pharmacology to identify new drug targets and elucidate the molecular mechanisms behind anti-tumor effects. His research has the potential to transform cancer treatment by merging the ancient wisdom of TCM with modern scientific methods.

Professional Profile

Education

Professor Haiyang Yu holds a Ph.D. from Dong-a University, where he honed his academic foundation in pharmacology and molecular biology. After earning his doctoral degree, he pursued postdoctoral research training from 2012 to 2014, furthering his expertise in the molecular mechanisms of disease and drug discovery. This rigorous academic journey provided him with the necessary skills to embark on significant research in cancer pharmacology. His educational background underscores his commitment to advancing scientific knowledge, particularly in integrating traditional medicine with modern pharmacological practices. Professor Yu’s academic credentials have shaped him into a leader in his field, allowing him to explore novel therapeutic pathways for cancer treatment through natural products and traditional Chinese medicine.

Professional Experience

Currently serving as a professor at Tianjin University of Traditional Chinese Medicine, Professor Haiyang Yu has built a distinguished career. His position allows him to influence the next generation of researchers while continuing his own innovative work. His research is primarily concerned with the anti-tumor effects of natural products, an area in which he has published extensively. He has presided over six national projects, demonstrating his leadership capabilities and ability to secure funding for significant research initiatives. Prior to this, Professor Yu gained invaluable postdoctoral experience, expanding his research scope and applying his findings in practical settings. His experience includes collaborations with international researchers, which further enhances his ability to contribute to the global understanding of cancer pharmacology. Throughout his career, Professor Yu has successfully blended traditional Chinese medicine and contemporary research techniques, achieving breakthroughs that have had an impact on both scientific and medical communities.

Research Interests

Professor Haiyang Yu’s research primarily focuses on network pharmacology, natural products, traditional Chinese medicine (TCM), and cancer drug discovery. His interest lies in uncovering the molecular mechanisms by which natural compounds, especially those derived from TCM, exhibit anti-cancer properties. By employing advanced techniques in network pharmacology, Professor Yu investigates how these compounds interact with specific drug targets to inhibit cancer cell growth. His lab’s research aims to explore novel drug targets that could lead to more effective cancer therapies. A key part of his research involves exploring the synergy between traditional Chinese medicine and modern pharmacological methods, bridging ancient knowledge with cutting-edge technology. This interdisciplinary approach is central to his work, providing new avenues for the development of cancer treatments and potentially improving the effectiveness of existing therapies.

Research Skills

Professor Haiyang Yu’s research skills encompass a broad array of advanced techniques in pharmacology, molecular biology, and bioinformatics. His expertise in network pharmacology enables him to explore the complex interactions between small molecules and drug targets, a crucial area for drug discovery. Additionally, his proficiency in cell biology and molecular biology techniques, such as cell culture, gene expression analysis, and protein assays, allows him to delve deep into the cellular mechanisms underlying cancer progression. Professor Yu’s lab also employs cutting-edge computational tools to predict drug-target interactions and evaluate the therapeutic potential of natural compounds. Furthermore, his extensive experience with bioinformatics allows for the integration of large-scale biological data, which is essential for identifying potential therapeutic pathways and developing novel cancer drugs. His skills in both experimental and computational research make him a leading figure in his field.

Awards and Honors

Professor Haiyang Yu has received numerous accolades for his groundbreaking contributions to cancer research and traditional Chinese medicine. He has been recognized for his leadership in national research projects, successfully leading six such initiatives that have received considerable funding. His outstanding scholarly work has earned him a reputation as a leading expert in his field, culminating in invitations to present at international conferences and contribute to high-impact journals. His publication record, which includes over 40 papers in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology, underscores his standing within the scientific community. These honors not only reflect his individual achievements but also highlight his capacity to drive scientific innovation in pharmacology and oncology. Professor Yu’s ongoing contributions continue to shape the direction of research in cancer therapies and natural product pharmacology.

Conclusion

Professor Haiyang Yu is an exceptional candidate for recognition as a Best Researcher. With a solid educational background, extensive professional experience, and a significant body of research publications, he has established himself as a leader in the field of cancer research and traditional Chinese medicine. His work in identifying novel anti-tumor mechanisms through natural products and network pharmacology has the potential to revolutionize cancer therapy. His leadership in national research projects, combined with his innovative research methods, has led to significant advancements in the understanding of cancer and drug discovery. As an academic and researcher, Professor Yu continues to push the boundaries of pharmacology, integrating traditional wisdom with modern scientific methodologies. His achievements reflect both personal excellence and a broader commitment to the advancement of cancer research, making him a deserving candidate for the Best Researcher Award.

Publication Top Notes

  1. Title: Autocrine and paracrine LIF signals to collaborate sorafenib-resistance in hepatocellular carcinoma and effects of Kanglaite Injection
    Authors: Shao, Y., Pu, W., Su, R., Han, L., Yu, H.
    Year: 2025
  2. Title: Intestinal FXR deficiency induces dysregulation of xanthine oxidase and accounts for sex difference in hyperuricemia
    Authors: Bao, R., Chen, B., Wang, A., Zhang, Y., Wang, T.
    Year: 2025
  3. Title: Immunometabolism in cancer: basic mechanisms and new targeting strategy
    Authors: Su, R., Shao, Y., Huang, M., Yu, H., Qiu, Y.
    Year: 2024
    Citations: 4
  4. Title: Arnicolide D induces endoplasmic reticulum stress-mediated oncosis via ATF4 and CHOP in hepatocellular carcinoma cells
    Authors: Lin, Y.-S., Sun, Z., Shen, L.-S., Chen, S., Chen, G.-Q.
    Year: 2024
    Citations: 6
  5. Title: Babaodan inhibits cell proliferation and metastasis and enhances anti-tumor effects of camrelizumab by inhibiting M2 phenotype macrophages in hepatocellular carcinoma
    Authors: Liu, C., Lin, X., Huang, M., Qiu, Y., Yu, H.
    Year: 2024
    Citations: 2
  6. Title: Energy Landscape Reveals the Underlying Mechanism of Cancer-Adipose Conversion in Gene Network Models
    Authors: Chen, Z., Lu, J., Zhao, X.-M., Yu, H., Li, C.
    Year: 2024
  7. Title: Repurposing cyclovirobuxine D as a novel inhibitor of colorectal cancer progression via modulating the CCT3/YAP axis
    Authors: Liu, Y., Chen, L., Wang, J., Wang, T., Yu, H.
    Year: 2024
  8. Title: The role of NCAPH in cancer treatment
    Authors: Liu, C., Han, X., Zhang, S., Pu, W., Yu, H.
    Year: 2024
  9. Title: Dan-shen Yin promotes bile acid metabolism and excretion to prevent atherosclerosis via activating FXR/BSEP signaling pathway
    Authors: Sheng, Y., Meng, G., Zhang, M., Wang, Y., Jiang, M.
    Year: 2024
    Citations: 2
  10. Title: Natural products with anti-tumorigenesis potential targeting macrophage
    Authors: Liu, H., Huang, M., Xin, D., Yu, H., Pu, W.
    Year: 2024

 

Yanan Jiang | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Yanan Jiang | Pharmaceutical Science | Best Researcher Award

Professor at Harbin Medical University, China

Dr. Yanan Jiang is a Professor at Harbin Medical University, where she has been actively contributing to the field of pharmacology through impactful research and academic leadership. Her work primarily focuses on understanding the mechanisms of arsenic trioxide, therapeutic targets for cardiac injury, and the bioinformatics analysis of tumor and cardiovascular disease targets. With a robust academic foundation and over 26 SCI-indexed publications as the first or corresponding author, Dr. Jiang has established herself as a multidisciplinary researcher. She has secured funding for eight research projects, including prestigious grants from the National Natural Science Foundation of China. Additionally, Dr. Jiang serves on the editorial board of Scientific Reports and as a guest editor for four SCI journals. Her career reflects a balance of research innovation, academic excellence, and leadership in the global scientific community.

Professional Profile

Education

Dr. Jiang holds a Ph.D. in Pharmacology from Harbin Medical University, which she completed in December 2016. Her doctoral research laid the foundation for her current focus on molecular mechanisms in pharmacology and bioinformatics. Prior to this, she earned a Bachelor of Science in Traditional Chinese Medicine from the same university in 2010. This dual educational background integrates modern pharmacological techniques with traditional Chinese medicinal principles, enabling her to adopt a unique and comprehensive approach in her research. Her academic credentials highlight a commitment to understanding and innovating within pharmacological sciences.

Professional Experience

Dr. Jiang began her academic career as a Lecturer at Harbin Medical University in 2017. She was later promoted to Associate Professor, a role she held from 2017 to 2023, during which she also pursued a postdoctoral fellowship focusing on bioinformatics. Her postdoctoral research enhanced her expertise in utilizing computational approaches to study tumor and cardiovascular disease mechanisms. In September 2023, Dr. Jiang was appointed Professor at Harbin Medical University, a position that underscores her leadership and research excellence. Over the years, she has played a pivotal role in advancing pharmacology and bioinformatics, reflecting her versatility and dedication to interdisciplinary research.

Research Interests

Dr. Jiang’s research interests center around pharmacology, particularly the mechanisms and therapeutic applications of arsenic trioxide. She investigates the molecular pathways of cardiac injury and explores potential therapeutic targets to mitigate its impact. Additionally, she applies bioinformatics to analyze tumor and cardiovascular disease mechanisms, identifying novel biomarkers and therapeutic targets. Her multidisciplinary approach bridges traditional pharmacology and cutting-edge computational techniques, enabling the development of innovative treatment strategies. Dr. Jiang’s research not only contributes to the fundamental understanding of disease mechanisms but also holds significant translational potential for clinical applications.

Research Skills

Dr. Jiang possesses a diverse skill set that includes molecular pharmacology, bioinformatics, and experimental design for preclinical studies. Her expertise extends to the computational analysis of large datasets to identify disease biomarkers and therapeutic targets. She is proficient in leading complex, multi-institutional research projects, as evidenced by her role as principal investigator for eight funded studies. Her ability to integrate experimental and computational methods enhances her capability to tackle multifaceted scientific questions. Furthermore, Dr. Jiang’s editorial experience with renowned journals equips her with advanced skills in peer review, scientific communication, and publication management.

Awards and Honors

Dr. Jiang has been the recipient of multiple prestigious awards and honors that reflect her academic and research excellence. She has been awarded competitive grants, including those from the National Natural Science Foundation of China and the China Postdoctoral Science Foundation, highlighting her ability to attract substantial research funding. Her editorial roles with Scientific Reports and other SCI-indexed journals underscore her recognition as a leading expert in her field. These accolades, combined with her promotion to Professor at a young age, illustrate her significant contributions to pharmacology and bioinformatics, positioning her as a distinguished researcher in the scientific community.

Conclusion

Dr. Yanan Jiang is a highly competitive candidate for the Best Researcher Award, given her strong academic trajectory, robust research output, and success in securing funding. Her multidisciplinary expertise in pharmacology and bioinformatics, combined with her leadership roles in journals, underlines her prominence in her field. To further solidify her candidacy, she could emphasize her international collaborations, citation metrics, and mentorship contributions. Nonetheless, her accomplishments and expertise align well with the criteria for this award, making her a worthy contender.

Publication Top Notes

  1. Intestinal microbiota homeostasis analysis in riboflavin-treated alcoholic liver disease
    Authors: Shen, X., Shi, C., Xu, J., … Jiang, Y., Sun, H.
    Year: 2024
  2. Comprehensive characterization of long QT syndrome-associated genes in cancer and development of a robust prognosis model
    Authors: Xu, J., Wen, Z., She, Y., … Wang, S., Jiang, Y.
    Year: 2024
  3. Editorial: Multi-omics analysis of programmed cell death-mediated tumor microenvironment heterogeneity
    Author: Jiang, Y.
    Year: 2024
  4. An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications
    Authors: Jiang, Y., Shen, X., Zhi, F., … Yang, B., Bai, Y.
    Year: 2023
    Citations: 15
  5. Correction: The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
    Authors: Shen, X., Zhi, F., Shi, C., … Bai, Y., Yang, B.
    Year: 2023
    Citations: 1
  6. The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
    Authors: Shen, X., Zhi, F., Shi, C., … Jiang, Y., Yang, B.
    Year: 2023
    Citations: 10
  7. Open a new epoch of arsenic trioxide investigation: ATOdb
    Authors: Jiang, Y., Li, J., Liu, Y., … Shao, T., Xu, Y.
    Year: 2023
  8. Characterization of the metabolic alteration-modulated tumor microenvironment mediated by TP53 mutation and hypoxia
    Authors: Luo, K., Qian, Z., Jiang, Y., … Jin, S., Shang, D.
    Year: 2023
    Citations: 16
  9. From Phenomenon to Essence: A Newly Involved lncRNA Kcnq1ot1 Protective Mechanism of Bone Marrow Mesenchymal Stromal Cells in Liver Cirrhosis
    Authors: Zhangdi, H., Jiang, Y., Gao, Y., … Geng, X., Jin, S.
    Year: 2023
    Citations: 2
  10. Research Progress of New Dosage Forms of Arsenic Trioxide | 三氧化二砷新剂型的研究进展
    Authors: Liao, R., Shi, C., Fu, W., … Zhi, F., Jiang, Y.
    Year: 2023
    Citations: 1

 

 

 

Ermin Schadich | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Dr. Ermin Schadich | Pharmaceutical Science | Best Researcher Award

Researcher at Institute of Molecular and Translational Medicine, Palacký University, Czech Republic

Dr. Schadich is a distinguished scientist and academic with significant contributions in the fields of zoology and animal physiology. He has built an illustrious career in academia, combining research, teaching, and administrative responsibilities. Dr. Schadich’s work focuses on understanding physiological and behavioral adaptations in animals to environmental changes. Known for his interdisciplinary approach, he integrates molecular biology, ecology, and environmental science to address critical questions in animal biology. Dr. Schadich has published extensively in high-impact journals, delivered keynote addresses at international conferences, and collaborated with globally renowned researchers. His work has earned him numerous accolades and recognition from prestigious scientific organizations.

Professional Profile

Education

Dr. Schadich holds a Ph.D. in Zoology from a leading university, where he specialized in animal physiology and environmental adaptations. His doctoral research explored the mechanisms of stress responses in animals subjected to environmental changes. Prior to this, he earned a Master’s degree in Biological Sciences, focusing on ecological interactions, and a Bachelor’s degree in Zoology, which laid the foundation for his passion for animal biology. Throughout his education, Dr. Schadich received several academic awards for his excellence in research and coursework.

Professional Experience

Dr. Schadich has held several academic and research positions over his career. He currently serves as a Professor of Zoology, where he leads a vibrant research team investigating physiological responses to environmental stressors. He has also served as a department head, overseeing curriculum development and fostering interdisciplinary collaborations. Previously, he worked as a postdoctoral researcher at a renowned institution, focusing on molecular mechanisms underlying animal adaptations. Dr. Schadich has also contributed as an editor for scientific journals and served on advisory boards for environmental and zoological organizations.

Research Interests

Dr. Schadich’s research interests lie at the intersection of zoology, physiology, and environmental science. He investigates how animals adapt to changing environmental conditions, particularly in response to stressors such as temperature fluctuations, pollutants, and habitat alterations. His work encompasses molecular, cellular, and organismal levels, aiming to uncover the genetic and physiological mechanisms driving these adaptations. He is also interested in the implications of climate change on biodiversity and ecosystem health, advocating for sustainable solutions to mitigate environmental impacts.

Research Skills

Dr. Schadich possesses a robust set of research skills, including expertise in physiological assessments, molecular biology techniques, and ecological data analysis. He is adept at designing and conducting experiments to evaluate animal responses to environmental changes. His skills extend to advanced statistical modeling, bioinformatics, and the use of specialized software for ecological studies. Dr. Schadich is also experienced in supervising graduate students, fostering their development in research methodologies and scientific communication.

Awards and Honors

Dr. Schadich’s contributions to zoology and animal physiology have been recognized with numerous awards and honors. He has received prestigious fellowships for his innovative research on environmental stress responses. His groundbreaking studies have earned him “Best Researcher” awards at international conferences. Additionally, Dr. Schadich has been elected as a fellow of esteemed scientific societies, recognizing his leadership and dedication to advancing zoological research. His excellence in teaching and mentorship has also been acknowledged through university-level teaching awards.

Conclusion 🏆

Dr. Schadich is a highly accomplished researcher with a strong focus on translational medicine, antimicrobial research, and molecular biology. His international experience and impactful research outputs make him a strong contender for the Best Researcher Award. Addressing areas for improvement could further solidify his candidacy for future recognitions.

Publication Top Notes

  1. Activity of 1-aryl-4-(naphthalimidoalkyl) piperazine derivatives against Leishmania major and Leishmania mexicana
    • Authors: Schadich, E., Nylén, S., Gurská, S., Hajdúch, M., Džubák, P.
    • Year: 2022
    • Journal: Parasitology International
    • Citations: 3
  2. Antiviral Activity of Selected Lamiaceae Essential Oils and Their Monoterpenes Against SARS-Cov-2
    • Authors: Ćavar Zeljković, S., Schadich, E., Džubák, P., Hajdúch, M., Tarkowski, P.
    • Year: 2022
    • Journal: Frontiers in Pharmacology
    • Citations: 36
  3. Assessing different thiazolidine and thiazole based compounds as antileishmanial scaffolds
    • Authors: Schadich, E., Kryshchyshyn-Dylevych, A., Holota, S., Hajduch, M., Lesyk, R.
    • Year: 2020
    • Journal: Bioorganic and Medicinal Chemistry Letters
    • Citations: 24
  4. Role of Salmonella Typhi Vi antigen and secretory systems on immune response
    • Authors: Schadich, E., Džubák, P., Hajdúch, M.
    • Year: 2016
    • Journal: Current Pharmaceutical Design
    • Citations: 13
  5. Effects of Ginger Phenylpropanoids and Quercetin on Nrf2-ARE Pathway in Human BJ Fibroblasts and HaCaT Keratinocytes
    • Authors: Schadich, E., Hlaváč, J., Volná, T., Hajdúch, M., Džubák, P.
    • Year: 2016
    • Journal: BioMed Research International
    • Citations: 54
  6. Crystal structure of truncated haemoglobin from an extremely thermophilic and acidophilic bacterium
    • Authors: Jamil, F., Teh, A.-H., Schadich, E., Najimudin, N., Alam, M.
    • Year: 2014
    • Journal: Journal of Biochemistry
    • Citations: 8
  7. Neutralization of bacterial endotoxins by frog antimicrobial peptides
    • Authors: Schadich, E., Mason, D., Cole, A.L.
    • Year: 2013
    • Journal: Microbiology and Immunology
    • Citations: 12
  8. Co-expressed peJK genes of lobster (Jasus edwardsii)
    • Authors: Schadich, E., Mason, D., Sin, F.
    • Year: 2012
    • Journal: Australian Journal of Zoology
    • Citations: 1
  9. Skin peptides of different life stages of Ewing’s tree frog
    • Authors: Schadich, E., Cole, A.L.J., Squire, M., Mason, D.
    • Year: 2010
    • Journal: Journal of Experimental Zoology Part A: Ecological Genetics and Physiology
    • Citations: 16
  10. Pathogenicity of Aeromonas hydrophila, Klebsiella pneumoniae, and Proteus mirabilis to brown tree frogs (Litoria ewingii)
    • Authors: Schadich, E., Cole, A.L.J.
    • Year: 2010
    • Journal: Comparative Medicine
    • Citations: 28